Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: gfp927z who wrote (1315)	11/25/2004 2:31:11 PM
From: Tony van Werkhooven	of 1386

GFP - There were three distinct cohorts in the Phase II study. I don't recall the results from memory. There was a problem with one of the cohorts - the Dex treated group had distinctly worse injuries. I would suggest that you pose your question on the Yahoo Pharmos board - Address them to GSR-Seatle - I am confident that he has the information readily available. Tony

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next